AXA-1125

N/A

Report date: 2023/12/11 16:23:59

Base Information

Drug NameAXA-1125

Drug Alias NameAXA-1125AXA1125

ClassificationSmall molecules > Amino acid supplement, Lipids and Vitamins

Mechanisms of Actionendogenous metabolic modulator

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesPoland +[7]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAxcella Health Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

ATC CodeN/A